Table 3 Clinico-pathological characteristics at primary diagnosis and Asp302His genotype distribution
From: Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer
| Â | All | CASP8 Asp302His genotype | P-value | ||
|---|---|---|---|---|---|
Asp/Asp | Asp/His | His/His | |||
n (%) | 200 | 151 (75.5) | 46 (23.0) | 3 (1.5) | Â |
Age at diagnosis (years ± SD) | 56.46 ± 12.1 | 57.46 ± 12.0 | 52.87 ± 11.7 | 61.33 ± 11.0 | 0.089 |
Tumor type | |||||
 Ductal | 136 (68.0) | 109 (80.1) | 24 (17.6) | 3 (2.2) | 0.086 |
 Lobular | 43 (21.5) | 29 (67.4) | 14 (32.6) | 0 (0) | |
 Others | 21 (10.5) | 13 (61.9) | 8 (38.1) | 0 (0) | |
Tumor size (mm ± SD) | 24.20 ± 16.8 | 23.54 ± 17.4 | 25.22 ± 14.4 | 50.00 ± 7.1 | 0.163 |
Tumor stage | |||||
 pT1 | 107 (53.5) | 84 (78.5) | 22 (20.6) | 1 (0.9) | 0.321 |
 pT2 | 71 (35.3) | 49 (69.0) | 21 (29.6) | 1 (1.4) | |
 pT3+4 | 22 (11.0) | 18 (81.8) | 3 (13.6) | 1 (6.7) | |
Lymph node status | |||||
 pN0 | 115 (57.5) | 92 (80.0) | 22 (19.1) | 1 (0.9) | 0.202 |
 pN+ | 85 (42.5) | 59 (69.4) | 24 (28.2) | 2 (2.4) | |
UICC stage | |||||
 I | 76 (38.0) | 59 (77.6) | 16 (21.1) | 1 (1.3) | 0.387 |
 II | 78 (39.0) | 58 (74.4) | 20 (25.6) | 0 (0) | |
 III + IV | 46 (23.0) | 34 (73.9) | 10 (21.7) | 2 (4.3) | |
Grade | |||||
 1 | 71 (37.4) | 56 (78.9) | 15 (21.1) | 0 (0) | 0.459 |
 2 | 68 (35.8) | 49 (72.1) | 18 (26.5) | 1 (1.5) | |
 3 | 51 (26.8) | 38 (74.5) | 11 (21.6) | 2 (3.9) | |
Estrogen receptor status | |||||
 negative | 53 (32.5) | 43 (26.4) | 10 (6.1) | 0 (0) |  |
 positive | 110 (67.5) | 81 (49.7) | 27 (16.6) | 2 (1.2) | 0.402 |
Her2 status | Â | Â | Â | Â | |
 negative | 138 (83.6) | 104 (63.0) | 32 (19.4) | 2 (1.2) |  |
 positive | 27 (16.4) | 21 (12.7) | 6 (3.6) | 0 (0) | 0.811 |
Treatment | |||||
 Surgical treatment | |||||
  breast conserving | 50 (25.0) | 41 (82.0) | 8 (16.0) | 1 (2.0) | 0.300 |
  ablative | 150 (75.0) | 110 (73.3) | 38 (25.3) | 2 (1.3) |  |
 Adjuvant therapy |  |  |  |  |  |
  no adjuvant therapy | 112 (56.0) | 90 (80.4) | 21 (18.8) | 1 (0.9) | 0.065 |
  Tam and/or CMF | 88 (44.0) | 61 (69.3) | 25 (28.4) | 2 (2.3) |  |
Tam and/or CMF | 88 (44.0) | 61 (69.3) | 25 (28.4) | 2 (2.3) | Â |